Podcasts about mitral

No Click Valvar de hoje temos grandes insights sobre a classificação etiológica na Insuficiência Mitral.

This special issue of JACC is dedicated to the essential role of cardiovascular surgery in advancing modern cardiology.

Commentary by Dr.  Jian'an Wang

No Click Valvar de hoje temos grandes insights sobre a presença de uma disjunção de anel mitral.

A 27-year-old woman presents as a new patient to your practice.  She is without chief complaint. She asks to, “get a refill on my birth control pills” , having used combined oral contraceptives for the past 12 years without adverse effects.  Social history reveals she is a nonsmoker, without recreational drug use, drinks approximately 1-2 mixed drinks per week, and runs 2-3 miles 5 days a week with reported excellent activity tolerance. Her health history is generally unremarkable, but with patient report of a “mild heart murmur that was picked up when I was a teenager during a physical I needed so I could run track. I was told not to worry about it.” Physical exam is unremarkable with the exception of a mid-systolic click followed by a grade II mid to late systolic murmur without radiation. The remainder of the cardiac exam is within normal limits.  These findings most likely represent which type of murmur? A. PhysiologicB. Aortic stenosis C. Mitral regurgitation D. Mitral valve prolapse---YouTube: https://www.youtube.com/watch?v=wmGI7v_DPMY&list=PLf0PFEPBXfq592b5zCthlxSNIEM-H-EtD&index=105Visit fhea.com to learn more!

No Click Valvar de hoje temos grandes insights sobre a aplicabilidade do strain de ventrículo direito em doenças da valva mitral.

No Click Valvar de hoje temos grandes insights sobre o prolapso de valva mitral.

Hey Heart Buddies! Boots Knighton speaks with Lucinda McDermott about navigating heart health after discovering a severely leaking tricuspid valve. Lucinda shares her journey, from initial chest pain and fainting to being diagnosed with a heart murmur by her OB GYN. After mitral valve replacement in 2017, Lucinda faced additional challenges, including fragmented healthcare and dismissive cardiologists. Both Lucinda and Boots stress the importance of patient advocacy, support networks like WomenHeart, and having a “heart doula” during medical appointments. The episode highlights key issues like secure insurance, patient empowerment, and the significance of clear communication with healthcare providers.Want to contact Lucinda? Email her: lucimc2319@gmail.comJoin the Newsletter for almost weekly content for this podcast and other heart related news.Join the Patreon Community! The Joyful Beat zoom group is where you'll find connection and hope that you aren't alone in your journey.If you just want to support the show as a one-time gift (thank you), go here.**I am not a doctor and this is not medical advice. Be sure to check in with your care team about all the next right steps for you and your heart.**How to connect with BootsEmail: Boots@theheartchamberpodcast.comInstagram: @openheartsurgerywithboots or @boots.knightonLinkedIn: linkedin.com/in/boots-knightonBoots KnightonIf you enjoyed this episode, take a minute and share it with someone you know who will find value in it as well. You can share directly from this platform or send them to:Open Heart Surgery with Boots Mentioned in this episode:Heart Valve Voice - USBe sure to check out HHV - US!HVV-US

As we step away for a holiday break, we're excited to revisit some of the most popular episodes of the FNP Certification Q & A Podcast. These listener favorites have informed, inspired, and empowered aspiring NPs on their journey to certification success. Enjoy some of our favorites. We'll catch you in 2025 with fresh questions from Dr. Fitzgerald!In evaluating a 66-year-old man with dilated cardiomyopathy and heart failure, the NP notes a grade 3/6 medium-pitched blowing systolic murmur that radiates to the axillae. What do these findings most likely represent?A.Innocent murmurB. Mitral stenosisC. Aortic regurgitationD. Mitral regurgitation---YouTube: https://www.youtube.com/watch?v=jhrYmC-kq6Y&list=PLf0PFEPBXfq592b5zCthlxSNIEM-H-EtD&index=102Visit fhea.com to learn more!

CLASP IID 2 Year: RCT and Registry: Two-Year Outcomes of Transcatheter Edge-to-Edge Repair for Degenerative Mitral Regurgitation

Degenerative or myxomatous mitral valve disease (MMVD) is a common canine cardiac disease. In this episode of the VetFolio Voice podcast, we discuss the importance of early diagnosis and treatment in order to slow the progression of this disease. Listen in as we chat about MMVD, from diagnosis through the preclinical stages of the disease. We review diagnostics that can be helpful in assessing this disease, such as thoracic radiographs and echocardiography, and what information can be obtained from each. We'll also explore how the treatment plan may change once the patient is symptomatic. Want to earn CE from this episode? Be sure to log into VetFolio and take the quiz to qualify for your CE credit! https://www.vetfolio.com/courses/treatment-of-preclinical-mitral-valve-disease-in-your-practice-podcast-quiz

Send us a textNeste episódio Luís Augusto e Williasmin Souza recebem o Dr. Roberto Cintra, Cardiologista e especialista e valvopatias e doenças estruturais pelo INCOR-HC-FMUSP para uma conversa sobre IM secundária.Vamos passear desde as possíveis etiologias, até o exame físico, avaliação ecocardiográfica e terapêutica. E os estudos que respaldam a intervenção percutânea: você conhece?Aperta o play e vamos até o final.

In today's VETgirl online veterinary CE podcast, we're going to talk about one of my favorite breeds, the super sweet Cavalier King Charles Spaniel (what we'll Cavaliers from now on, since it's a mouthful!). Unfortunately, we all know that this breed has horrible myxomatous mitral valve disease. So, if you see Cavaliers in your clinic, when should you decide to put these dogs on heart medications? After all, we know that the initiation of pimobendan can significantly delay the onset of congestive heart failure in dogs with stage B2 myxomatous mitral valve disease (or “mitral valve disease”), and that detection of the transition from stage B1 to B2 in this population of dogs is important so that therapy can be initiated expediently.Sponsored By: Antech

In this episode, Dr. Valentin Fuster delves into the latest research surrounding the use of the mitral clip for patients with severe functional mitral regurgitation, comparing the results of three major trials: the French MITRA-FR trial, the American COAPT trial, and the Reshape HF 2 trial. While the COAPT and Reshape HF 2 trials show positive outcomes, especially in reducing hospitalizations and improving heart failure symptoms, the French trial saw no benefit, prompting debate over the influence of left ventricular volume and disease severity on treatment success, with expert opinions calling for further studies and individualized meta-analyses.

In this episode, Dr. Valentin Fuster delves into the latest research surrounding the use of the mitral clip for patients with severe functional mitral regurgitation, comparing the results of three major trials: the French MITRA-FR trial, the American COAPT trial, and the Reshape HF 2 trial. While the COAPT and Reshape HF 2 trials show positive outcomes, especially in reducing hospitalizations and improving heart failure symptoms, the French trial saw no benefit, prompting debate over the influence of left ventricular volume and disease severity on treatment success, with expert opinions calling for further studies and individualized meta-analyses.

JACC: Case Reports Associate Editor Maurizio Taramasso, MD, PhD, joins author Brinder S Kanda, MD, FACC to discuss their case presented at AHA and published in JACC: Case Reports. In this case, an 83-year-old female with decompensated heart failure was found to have HOCM with SAM of the mitral valve and a large P2 flail segment with ruptured cords. TEER was performed resulting in mild MR and resolution of the prior LVOT gradient. The case supports TEER for patients with medication-refractory HOCM.

RESHAPE-HF2 – Percutaneous Repair of Moderate-to-Severe or Severe Functional Mitral Regurgitation in Patients with Symptomatic Heart Failure

In this podcast, Dr. Valentin Fuster discusses a groundbreaking study on using artificial intelligence (AI) in electrocardiograms (ECGs) to assess left ventricular diastolic function and predict outcomes in patients with significant mitral regurgitation. The study demonstrates that AI-driven ECGs can offer comparable prognostic value to traditional echocardiography, identifying high-risk patients and potentially revolutionizing cardiovascular diagnostics, though challenges around sensitivity, specificity, and patient selection remain.

Join our hosts Can Gollmann-Tepeköylü and Miia L Lehtinen for their late-breaking trials highlights presented at the 38th EACTS Annual Meeting in Lisbon, including: (0:39 - 4:31) Long-term mortality after PCI or CABG in patients with diabetes and multivessel coronary artery disease: A SWEDEHEART study by Dr Emma C Hansson (4:32 - 8:33) Long-term (>10 years) results of transcatheter Mitral valve-in-valve implantation for degenerated surgical mitral bioprosthesis: Italian MItral VIV registry (MIVIV registry) by Dr Edoardo Zancanaro  (8:34 - 11:55) Personalized multimodal teleprehabilitation in elective cardiac surgery: results from the Digital Cardiac Counselling multicentered randomized Controlled Trial (ClinicalTrials.gov number, NCT04393636.) by Dr Bart Scheenstra   (11:55 - 16:15) 5-Year Results on Aortic Remodeling in the Dissected Aorta Repair Through Stent (DARTS) Implantation Trial by Dr Ryaan EL-Andari (16:16 - 19:49) Clinical impact of continuous postoperative pericardial flushing on bleeding-related complications after cardiac surgery by Dr Robert Klautz

Mirza Umair Khalid, MD, social media editor of JACC: Cardiovascular Interventions, and Thomas J. Stocker, MD, discuss a recently published original research paper reporting the long-term outcomes after mitral transcatheter edge-to-edge repair for secondary mitral regurgitation.

JACC: Case Reports Associate Editor Maurizio Taramasso, MD, PhD, joins author Brinder S Kanda, MD, FACC to discuss their case presented at AHA and published in JACC: Case Reports. In this case, an 83-year-old female with decompensated heart failure was found to have HOCM with SAM of the mitral valve and a large P2 flail segment with ruptured cords. TEER was performed resulting in mild MR and resolution of the prior LVOT gradient. The case supports TEER for patients with medication-refractory HOCM.

No Click Valvar de hoje temos grandes insights sobre os resultados do Clip na valva mitral.

MATTERHORN – Transcatheter Versus Surgical Mitral Valve Repair in Patients With Heart Failure and Secondary Mitral Regurgitation

In this episode of the JACC: Asia podcast, Editor-in-Chief Jian'an Wang examines the EXPAND G4 study and evaluates the one-year outcomes of the first-generation Edge-to-Edge mitral valve repair device in 95 Japanese patients, demonstrating a 100% implantation success rate and significant improvements in mitral regurgitation severity and functional capacity. These promising results underscore the potential of this device to deliver excellent clinical outcomes for Asian patients with mitral valve disease.

Novel Mitral Therapies   Guest: Arman Arghami, M.D., M.P.H. Guest: Mayra Guerrero, M.D. Host: Kyle Klarich, M.D.   And the end of this podcast, the listener should understand how to identify new minimally invasive procedures to treat patients with mitral valve disease, delineate the difference between minimally invasive surgery versus percutaneous transcatheter interventions for mitral valve disease, and recognize when to refer patients for mitral valve interventions.   Topics Discussed: What are the minimally invasive intervention options to treat patient with mitral valve disease? Which are the patients who benefit from less invasive procedures? How and when to refer a patient for mitral valve intervention? If a patient had prior mitral valve surgery (repair or replacement) and has recurrent mitral valve disease, is redo mitral surgery always needed? Or can a patient with prior surgery be treated with a transcatheter mitral valve repair or replacement, avoiding the need for repeat surgery?   Connect with Mayo Clinic's Cardiovascular Continuing Medical Education online at https://cveducation.mayo.edu or on Twitter @MayoClinicCV and @MayoCVservices. LinkedIn: Mayo Clinic Cardiovascular Services Cardiovascular Education App: The Mayo Clinic Cardiovascular CME App is an innovative educational platform that features cardiology-focused continuing medical education wherever and whenever you need it. Use this app to access other free content and browse upcoming courses. Download it for free in Apple or Google stores today! No CME credit offered for this episode. Podcast episode transcript found here.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Von Willebrand factor activity association with outcomes after transcatheter edge-to-edge mitral valve repair.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on the impact of residual transmitral mean pressure gradient on outcomes after mitral transcatheter edge-to-edge repair.

Message our hosts, Kieran and Jose.Mitral valve disease is the most common heart disease diagnosed in dogs. Our understanding of it affects how we manage a wide range of scenarios, from asymptomatic heart murmurs detected at annual vaccination, to patients with respiratory signs or those about to undergo sedation or anaesthesia, or simply receive fluid therapy. Join Professor Michele Borgarelli, from the Virginia Maryland College of Veterinary Medicine, as he speaks to Kieran and Jose about an innovative dataset on over 6000 dogs with mitral valve disease, the LOOK-Mitral Registry, and how research like this can inform decision making in the clinic.

#67 Joel Oliver, a heart surgery patient from Calgary, Canada shares his mitral valve replacement with a mechanical valve in 2018. Despite the initial struggles during recovery, Joel has since lived a full and active life. He emphasizes the importance of maintaining hope and patience through the difficult recovery period. Joel also discusses his current medications and how, aside from these, he feels no lasting impact from his surgery. More about Joel: Joel Oliver is the owner and founder of East Coast Studio, a podcast production company which helps entrepreneurs enjoy the benefits of podcasting, while making the process as smooth as possible. Since starting as a solo freelancer a decade ago, Joel's knowledge and skills evolved to grow the business to what it is today, notably through a major heart surgery in 2018 where he was forced to let go of the reigns and fully trust the team he had built. After surgery, Joel spent several years as a digital nomad. He remains at the heart of the company, seamlessly balancing the distinctive challenges and freedoms that come with entrepreneurial work. https://www.linkedin.com/in/joel-ecs/https://eastcoaststudio.com/Email Joel: joel@eastcoaststudio.comJoin the Patreon Community! The Joyful Beat zoom group starts in September 2024.**I am not a doctor and this is not medical advice. Be sure to check in with your care team about all the next right steps for you and your heart.**How to connect with BootsEmail: Boots@theheartchamberpodcast.comInstagram: @openheartsurgerywithboots or @boots.knightonLinkedIn: linkedin.com/in/boots-knightonBoots KnightonIf you enjoyed this episode, take a minute and share it with someone you know who will find value in it as well. You can share directly from this platform or send them to:Open Heart Surgery with Boots

Editor-in-Chief Eric Rubin and Deputy Editor Jane Leopold discuss research that was presented at the 2024 European Society of Cardiology annual meeting. Visit NEJM.org to read the latest research.

Editor-in-Chief Eric Rubin and Deputy Editor Jane Leopold discuss research that was presented at the 2024 European Society of Cardiology annual meeting. Visit NEJM.org to read the latest research.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances discusses a recently published original research paper on clinical and 2/3D-echo determinants of mitral valve reoperation in children with congenital mitral valve disease

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances discusses a recently published original research paper on a novel hemodynamic index characterizing mitral regurgitation undergoing transcatheter edge to edge repair

In the inaugural episode of our newest podcast, Structural Heart Talks, we sit down with Daveen Chopra, Corporate VP and GM of Transcatheter Mitral and Tricuspid Therapies (TMTT) at Edwards Lifesciences. In the episode, Chopra discusses the unique challenges of advancing therapies for the mitral and tricuspid valves, which have historically been more difficult to treat than the aortic valve due to their complex and varied nature. He details Edwards Lifesciences' efforts to innovate in this space with technologies like the PASCAL valve repair system and the EVOQUE tricuspid valve replacement system, the first transcatheter tricuspid valve replacement approved in both the US and Europe. Later, Chopra explains the importance of a focused approach at Edwards Lifesciences, where the company's specialization in structural heart disease enables deeper knowledge and more targeted innovation. The conversation also explores the intricate process of planning and executing these advanced procedures, which require close collaboration between interventional cardiologists and echocardiographers. Chopra underscores the ongoing commitment to clinical evidence and real-world outcomes as key drivers of future success in this rapidly evolving field. Looking ahead, he emphasizes the need to increase awareness, diagnosis, and treatment rates for valve diseases, noting that many patients still go untreated due to a lack of awareness. Thank you to Resonetics for sponsoring this episode of Structural Heart Talks. To learn more about how Resonetics supports medical device companies, visit: https://shorturl.at/E1wO8 Thank you for listening to the Structural Heart Talks podcast. Tune in and subscribe to the DeviceTalks Podcast Network wherever you get your podcasts and follow youtube.com/@DeviceTalks or the Structural Heart Talks on YouTube Podcasts to ensure you never miss an episode.

Commentary by Dr. Candice Silversides

Does your heart start to race when you identify a new murmur in your canine patients? In this episode of Clinician's Brief Partner Podcast, host Dr. Beth Molleson gets advice from veterinary cardiologist Dr. Geri Lake-Bakaar on how to navigate myxomatous mitral valve disease, the most common heart disease in dogs. Dr. Lake-Bakaar shares valuable insights into diagnosing, staging, and monitoring heart disease in general practice and shares tips for distinguishing respiratory disease from congestive heart failure.Sponsored by BionoteResource:https://www.bionote.com/Contact us:Podcast@briefmedia.comWhere to find us:Cliniciansbrief.com/podcastsFacebook.com/clinciansbriefTwitter: @cliniciansbriefInstagram: @clinicians.briefThe Team:Beth Molleson, DVM - HostSarah Pate - Producer & Project Manager, Brief StudioRandall Stupka - Podcast Production & Sound Editing

CardioNerds cofounder, Amit Goyal joins Dr. Belal Suleiman, Dr. Nkiru Osude, and Dr. David Elliott from Duke University. They discuss a case of severe mitral paravalvular regurgitation complicated by hemolytic anemia. Expert commentary is provided by Dr. Andrew Wang. Audio editing by CardioNerds Academy Intern, student doctor Adriana Mares. US Cardiology Review is now the official journal of CardioNerds! Submit your manuscript here. CardioNerds Case Reports PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Case Media - Severe Mitral Paravalvular Regurgitation Complicated by Hemolytic Anemia - Duke University

A trip to the cardiologist is not always possible for every patient with myxomatous mitral valve disease (MMVD), which is why it is critical for the general practitioner to feel confident in the management of MMVD. In this episode of Clinician's Brief Partner Podcast, host Dr. Beth Molleson sits down with cardiologist Dr. Wendy Ware to discuss the current guidelines for medical intervention in MMVD, including how earlier intervention can lead to better outcomes.Sponsored by Boehringer IngelheimResource:vetmedin.comContact us:Podcast@briefmedia.comWhere to find us:Cliniciansbrief.com/podcastsFacebook.com/clinciansbriefTwitter: @cliniciansbriefInstagram: @clinicians.briefThe Team:Beth Molleson, DVM - HostSarah Pate - Producer & Project Manager, Brief StudioRandall Stupka - Podcast Production & Sound Editing 

New name, same podcast!At seven weeks old, Emily Falcon had a heart attack and was diagnosed with anomalous origin of the left coronary artery from the pulmonary artery (ALCAPA). This led to two open-heart surgeries, one at age six and another at age thirty-five. She loves travel and animals, both of which have helped her get through difficult times. While living a constrained life, Emily has sought out adventures whenever she can, such as trekking up volcanoes to observe mountain gorillas in Uganda, volunteering with cheetahs and baboons in Namibia, playing with wolves at the Arctic Circle, and eating with orangutans in Singapore. She is now an athlete who participates in a weekly run club and runs in 5K races throughout the year. She hopes to inspire others who have health limitations to never waste a moment and not let life pass them by. Emily Falcon lives in Massachusetts. She can be emailed at dont.waste.a.second.press@gmail.com.https://player.captivate.fm/episode/fc7195c7-5d95-4c08-a005-839b19ac1cbe

You know that conversation that you have with your client when you first diagnose congestive heart failure in their mitral valve disease dog? The one where you say: 'This will be the thing that kills your pet.' Well, that conversation is changing. Veterinary cardiologists  Dr Brad Gavaghan and Dr Fiona Meyers  introduce us to TEER (Transcatheter Edge-to-Edge Repair), a minimally invasive procedure that can completely change the outcome for your mitral valve patients. In this episode they explain how it works, what the procedure involves, and what the risks are. They also guide us through selecting the right patients for this procedure so you don't miss the window of opportunity, and outline a new approach for screening and monitoring your newly diagnosed heart murmur patients now that the paradigm of care has shifted. We get into the practicalities of referring your patients, including setting expectations and cost of the procedure.  This episode is from our RACE approve clinical podcast series. Join our Vet Vault Nerds at vvn.supercast.com for more updates, refreshers, pro tips, and show note with over 450 episodes in Small Animal Medicine, Surgery and Emergency and Critical Care. Serious surgeons, interns, residents and membership candidates should check out our new Advanced Surgery Podcast for a deep level of foundational surgery content. Subscribe to our ⁠weekly newsletter⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠here⁠⁠⁠⁠⁠⁠ for Hubert's favourite clinical and non-clinical learnings from the week.  --- Send in a voice message: https://podcasters.spotify.com/pod/show/vet-vault/message

In this VETgirl podcast, we interview Dr. Brian Scansen, DACVIM on mitral valve disease in dogs and what we need to do. What role do radiographs have in the management of mitral valve disease in dogs, and when should we consider starting medications in dogs with mitral valve disease in dogs? Get the low down on if compounded medications like compounded pimobendan is the same as Vetmedin (pimobendan), and what's new in the treatment of chronic valvular heart disease (CVHD) in dogs!

Joanne, Bernardo Siqueira e Guilherme Moura discutem sobre os principais pontos no diagnóstico e tratamento das valvopatias mitrais.

The Centers for Disease Control and Prevention (CDC) estimate about 2.5% of the US population, or 7.5 million Americans, are living with mitral valve disease. As the population ages, mitral valve disease may become more prevalent in a primary care or clinical cardiologist's practice. Listen to Dr. Yashasvi Chugh address what clinicians need to know for their patients they suspect need a mitral valve specialist.

Centers for Disease Control and Prevention (CDC) estimate about 2.5% of the US population, or 7.5 million Americans, are living with mitral valve disease. Aging is a major contributing factor to mitral valve disease so the number of individuals with the condition is expected to grow as the population ages. What is the mitral valve? How does it work? What causes mitral valve disease and what are the symptoms? How is the condition diagnosed and how is it treated? The answers to these questions are in this HeartSpeak podcast.

Commentary by Dr. Valentin Fuster

Degenerative mitral valve disease is the most common heart valve abnormality. Panayotis Vardas, M.D., a cardiothoracic surgeon, reviews the distinctions between primary and secondary mitral regurgitation. He describes categories of patients who would be candidates for mitral valve repair, which is the standard-of-care treatment, versus those who might undergo mitral valve replacement. Learn more about the dramatic success rates of mitral valve repair and clinical trials underway that explore new techniques for complex cases.

Today, we're going to talk about the #1 nutrient deficiency involved with mitral valve prolapse syndrome. If you have mitral valve prolapse, your heart valves are not opening and closing correctly. Mitral valve prolapse causes floppy, leaky valves that are large and bulging. This bulging, displaced tissue is called prolapse, which leads to inefficient heart pumping. Mitral valve prolapse symptoms include weakness, fatigue, palpitations, anxiety, and shortness of breath. It's often described as idiopathic, which means it has no known cause. Mitral valve prolapse is generally treated with beta-blockers or a calcium channel blocker. In a double-blind study, 141 subjects with mitral valve prolapse were compared to 40 healthy subjects. Sixty percent of the mitral valve prolapse group had magnesium deficiency compared to only 5% of the healthy subjects. Low magnesium leads to high adrenaline. It also accelerates the aging of the fibroblast cell, which helps you make collagen, elastin, and hyaluronic acid. As we age, the fibroblast cell is very important for our skin, ligaments, tendons, and valves. One of the first signs of magnesium deficiency is tetany. Surprisingly, 85% of people with mitral valve prolapse have tetany! Don't just rely on the RDA if you're deficient in magnesium. Try taking 400 mg 2 to 3 times a day, working up to this amount slowly. Also, ensure you're getting enough vitamin D. Magnesium won't work without vitamin D! Avoid sugar and refined carbs because they significantly decrease magnesium. It takes years for a magnesium deficiency to show up and it can take up to a year to correct. Try magnesium glycinate to increase your magnesium levels over time. DATA: https://www.ajconline.org/article/S00... https://pubmed.ncbi.nlm.nih.gov/3014234/ https://pubmed.ncbi.nlm.nih.gov/15945...

Do you know you valvulopathies? Learn everything there is to know about mitral stenosis! This episode was written by Dr. David Ji (Internal Medicine Resident) and reviewed by Dr. Murray Kornbluth (Cardiology) and Dr. Samuel Mamane (General Internal Medicine). Infographic by Julie Simone (Medical Student). Support the show

In today's VETgirl online veterinary CE podcast, we review the clinical signs, clinical course and prognosis for dogs diagnosed with pericardial effusion secondary to either left atrial rupture from myxomatous mitral valve disease versus those with neoplastic cardiac tamponade. This is based off a recent study by Sugiura et al entitled “Retrospective evaluation of clinical signs, clinical course, and prognosis between dogs with left atrial rupture secondary to myxomatous mitral valve disease and those with neoplastic cardiac tamponade (2015-2019): 70 cases.”

We know cardiac surgery can seem a bit daunting on the surface. However, most surgeons will come across cardiac surgery patients at some point whether in the OR, ICU, ED, etc. As the FIRST cardiac surgery specialty team for Behind the Knife, we are excited to bring you episodes focused on high-yield topics to help you navigate common cardiac surgery challenges, discuss relevant literature to help you in practice, and help our listeners feel more comfortable around cardiac surgery patients.  In this episode we'll discuss mitral valve disease. We'll review important physiologic differences in patients with mitral valve disease, the most common surgical approaches to address mitral valve disease, and how to work up and address acute mitral regurgitation due to acute papillary muscle rupture.  Hosts:  - Jessica Millar, MD- PGY-5 General Surgery Resident, University of Michigan, @Jess_Millar15 - Aaron William, MD- Cardiothoracic Surgery Fellow, Duke University, @AMWilliamsMD - Nick Teman, MD- Assistant Professor of Thoracic and Cardiovascular Surgery, University of Virginia, @nickteman Learning objectives: - Understand the physiologic differences that occur with mitral valve stenosis and regurgitation.  - Understand the basic principles of mitral valve repair and replacement strategies.  - Understand the presentation, work-up, and acute management of acute mitral valve regurgitations due to acute papillary muscle rupture/MI.   For episode ideas/suggestions/feedback feel free to email Jessica Millar at: millarje@med.umich.edu **Introducing Behind the Knife's Trauma Surgery Video Atlas - https://app.behindtheknife.org/premium/trauma-surgery-video-atlas/show-content The Trauma Surgery Video Atlas contains 24 scenarios that include never-before-seen high-definition operative footage, rich, original illustrations, and practical, easy-to-read pearls that will help you dominate the most difficult trauma scenarios.